当前位置： SCI文献检索 > DIABETES CARE期刊下所有文献 > Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.

Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.

Abstract：

OBJECTIVE:β-Cell autoantibodies are a feature of the preclinical phase of type 1 diabetes. Here, we asked how frequently they revert in a cohort of children at risk for type 1 diabetes and whether reversion has any effect on type 1 diabetes risk. RESEARCH DESIGN AND METHODS:Children were up to 10 years of age and screened more than once for insulin autoantibody, GAD antibody, and insulinoma antigen-2 antibodies. Persistent autoantibody was defined as an autoantibody present on two or more consecutive visits and confirmed in two reference laboratories. Reversion was defined as two or more consecutive negative visits after persistence. Time-dependent Cox regression was used to examine how reversion modified the risk of development of multiple autoantibodies and type 1 diabetes. RESULTS:Reversion was relatively frequent for autoantibodies to GAD65 (19%) and insulin (29%), but was largely restricted to children who had single autoantibodies (24%) and rare in children who had developed multiple autoantibodies (<1%). Most (85%) reversion of single autoantibodies occurred within 2 years of seroconversion. Reversion was associated with HLA genotype, age, and decreasing titer. Children who reverted from single autoantibodies to autoantibody negative had, from birth, a risk for type 1 diabetes of 0.14 per 100 person-years; children who never developed autoantibodies, 0.06 per 100 person-years; and, children who remained single-autoantibody positive, 1.8 per 100 person-years. CONCLUSIONS:Type 1 diabetes risk remained high in children who had developed multiple β-cell autoantibodies even when individual autoantibodies reverted. We suggest that monitoring children with single autoantibodies for at least 1 year after seroconversion is beneficial for stratification of type 1 diabetes risk.

journal_name

Diabetes Care

journal_title

Diabetes care

authors

Vehik K,Lynch KF,Schatz DA,Akolkar B,Hagopian W,Rewers M,She JX,Simell O,Toppari J,Ziegler AG,Lernmark Å,Bonifacio E,Krischer JP,TEDDY Study Group.

doi

10.2337/dc16-0181

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

1535-42

issue

eissn

0149-5992

issn

1935-5548

pii

dc16-0181

journal_volume

pub_type

杂志文章

在线工具

Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.